Login to Your Account

FDA Nixes Cellegy Pain Drug; Stock Takes Half-Off Nosedive

By Randall Osborne

Monday, April 29, 2002
Cellegy Pharmaceuticals Inc.’s stock tumbled more than 50 percent on news that the company is withdrawing the new drug application for Cellegesic, its nitroglycerin ointment for the treatment of pain from anal fissures. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription